Is Wegovy Safe?

• Wegovy (semaglutide) is a GLP-1 receptor agonist – a medication that mimics a natural hormone controlling your appetite and blood sugar.
• It’s licensed in the UK for weight management in adults with a BMI of 30 or higher, or 27-30 with at least one weight-related condition, when used alongside diet and activity changes.
• Some people experience mild, short-term side effects as their body adjusts, such as nausea, bloating, or tiredness.
• The key to safety is using it under clinical supervision with ongoing support.

The active ingredient, semaglutide, mimics a hormone called GLP-1 that helps regulate your appetite and blood sugar. It tells your brain you’re full sooner and slows digestion so you stay satisfied for longer. This makes it easier to eat less and form new, sustainable habits.

But Wegovy isn’t a “quick fix.” It’s most effective and safest when used alongside a balanced diet, regular movement, and coaching support.

Everyone’s body and medical history are different. Wegovy can be life-changing for some, but not suitable for everyone.

It may be safe and appropriate if you:

• Are 18 or older
• Have a BMI ≥ 30, or ≥ 27 with a related health condition
• Are not pregnant or breastfeeding
• Have no history of medullary thyroid cancer or MEN2
• Are committed to combining medication with lifestyle changes

At Medicspot, we don’t prescribe Wegovy if you:

• Are pregnant, planning pregnancy, or breastfeeding
• Have a history of severe stomach or kidney problems
• Have had pancreatitis in the past – in most cases, Wegovy would not be recommended
• Have a personal or family history of certain thyroid cancers (MEN2)
• Are using another GLP-1 medication (e.g., Mounjaro)
• Have had allergic reactions to semaglutide or similar medicines
• Are aged under 18 or over 75

If any of these apply to you, your prescriber will suggest safer alternatives.

Most of the clinical evidence we have so far shows that Wegovy is safe and well-tolerated when used long-term, with large trials following patients for more than two years. Research continues to show stable safety profiles over extended periods⁴, particularly when the medication is used under regular medical supervision.

In the UK, NICE currently recommends using Wegovy for up to two years within a specialist weight management service³. This doesn’t mean it becomes unsafe after that point – it simply reflects how long the clinical trials have followed people so far.

Around the world, many patients continue GLP-1 treatments beyond two years, especially when they have obesity-related health conditions that benefit from ongoing weight management.

If longer-term treatment is appropriate for you, your Medicspot prescriber will review your progress, discuss the evidence we have, and ensure it remains safe, effective, and in line with your health needs.

Most people tolerate Wegovy well, especially when the dose is increased gradually. The most common Wegovy side effects happen during the first few weeks and include:

• Nausea or vomiting – Eat smaller, lighter meals, avoid greasy foods
• Constipation – Stay hydrated, add fibre to your diet
• Diarrhoea – Rehydrate with fluids and electrolytes
• Headache or fatigue – Rest and maintain blood sugar balance

Side effects usually ease as your body adapts.

• Pancreatitis (inflammation of the pancreas) – seek urgent care if you have severe stomach pain or vomiting
• Gallbladder problems – report abdominal pain, fever, or jaundice
• Low blood sugar – mainly if used with diabetic medications
• Possible DKA risk – particularly if insulin doses are reduced or stopped too quickly. Never change your insulin without medical advice.
• Pregnancy risk – must be stopped before conception
• Surgery and anaesthesia – because Wegovy slows stomach emptying, there is a small increased risk of food remaining in your stomach during a general anaesthetic. Always tell your surgical and anaesthetic team that you’re taking Wegovy. They may adjust your fasting instructions or advise a temporary pause.

Medicspot clinicians monitor your progress closely. If any issues arise, they adjust or stop your treatment for your safety.

• Wegovy is taken once a week as a subcutaneous (under the skin) injection.
• Your prescriber will start you on a low dose (0.25mg) and gradually increase it over several months.
• Wegovy pens are multi-dose pens that deliver 4 doses per pen – one injection each week for 4 weeks.
• Store your pen in the fridge until ready to use.
• Always follow the manufacturer’s instructions and your clinician’s guidance.

At Medicspot, you’re not left on your own after your first prescription. We provide:

• Regular clinical reviews to track your progress
• Health coach support for lifestyle changes
• Access to educational resources on nutrition, sleep, and exercise
• Ongoing safety monitoring to ensure you stay within UK prescribing guidelines

Wegovy is typically prescribed for up to two years. After stopping, some weight regain is common, especially without continued support.

In follow-up studies, participants regained around two-thirds of their lost weight after discontinuation if they didn’t maintain behavioural changes¹.

That’s why we include 12 months of free aftercare once you finish your programme, helping you maintain your new habits, check in with your coach, and keep your results.

If you’re switching from Mounjaro or another GLP-1 medication, or transferring care to Medicspot, it’s important to do this safely.

Our clinical team reviews your dose history to minimise side effects. You’ll need to provide proof of your current prescription so we can ensure continuity and safety.

Wegovy is a clinically proven, well-researched treatment for weight management in the UK. It is safe when:

• Prescribed by a qualified healthcare professional
• Used within UK NICE and MHRA guidelines
• Combined with healthy lifestyle changes
• Regularly monitored with clinical and behavioural support

It is not safe when bought online without prescription or taken without proper follow-up care.

If you’re considering Wegovy and want to know if it’s right for you, start with our free online assessment.

¹ Wilding, J.P.H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism (2022). Last accessed November 2025. [https://pubmed.ncbi.nlm.nih.gov/35441470/]

² MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Updated Aug 2025. Last accessed November 2025. [https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know] 

³ NICE TA875. Semaglutide for managing overweight and obesity. March 2023. Last accessed November 2025. [https://www.nice.org.uk/guidance/ta875]

⁴ Ryan D.H., Lingvay I., Deanfield J., Kahn S.E., Barros E., Burguera B., Colhoun H.M., et al. “Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial”. Nature Medicine. 2024 Jul;30(7):2049–2057. doi:10.1038/s41591-024-02996-7. [https://pubmed.ncbi.nlm.nih.gov/38740993/]

NHS England. Weight-management medicines (GLP-1 receptor agonists) for obesity. Last accessed October 2025. [https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/]

Diabetes UK. Wegovy and GLP-1 medications – how they help with weight loss.
Last accessed October 2025. [https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/semaglutide/wegovy]

This article is for general information only and should not be used for the diagnosis or treatment of medical conditions. Medic Spot Limited has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. In the event of an emergency, please call 999 for immediate assistance.

There is no guarantee of a specific weight loss medication being prescribed. Clinicians will review your online questionnaire and will recommend the most appropriate weight loss treatments for you based on your answers. In some cases the clinicians may contact you for additional information. See our Terms of Service for more information.